| Domain |
Quality Indicator |
Facility |
State |
Facility rank (#1 is best) |
| For the Quality Indicators below, a lower percentage is better. |
| Psychosocial |
Worsening or serious resident behavior problems (LS) |
5.4% |
8.4% |
125 of
326 |
| Psychosocial |
Prevalence of depressive symptoms (LS) |
3.3% |
4.1% |
166 of
325 |
| Quality of Life |
Prevalence of physical restraints (LS) |
0.0% |
0.0% |
1 of
326 |
| Continence |
Worsening or serious bowel incontinence (LS) |
26.8% |
30.5% |
119 of
326 |
| Continence |
Worsening or serious bladder incontinence (LS) |
14.6% |
29.9% |
30 of
326 |
| Continence |
Prevalence of occasional to full bowel incontinence without a toileting plan (LS) |
22.9% |
93.9% |
2 of
314 |
| Continence |
Prevalence of occasional to full bladder incontinence without a toileting plan (LS) |
14.5% |
84.8% |
2 of
318 |
| Continence |
Prevalence of indwelling catheter (LS) |
0.8% |
2.3% |
106 of
326 |
| Infections |
Prevalence of urinary tract infections (LS) |
1.1% |
2.9% |
76 of
326 |
| Infections |
Prevalence of infections (LS) |
4.8% |
2.4% |
277 of
324 |
| Accidents |
Percent of residents experiencing one or more falls with major injury (LS) |
0.0% |
0.7% |
1 of
326 |
| Nutrition |
Prevalence of unexplained weight loss (LS) |
2.4% |
4.3% |
81 of
326 |
| Skin Care |
Prevalence of pressure sores in high risk residents (LS) |
1.7% |
5.1% |
32 of
322 |
| Psychotropics |
Prevalence of anti-psychotics without a diagnosis of psychosis (LS) |
1.6% |
9.0% |
26 of
321 |
| Functioning |
Worsening or serious functional dependence (LS) |
n/a |
|
n/a of
0 |
| Functioning |
Worsening or serious mobility dependence (LS) |
n/a |
|
n/a of
0 |
| Functioning |
Worsening or serious range of motion limitation (LS) |
4.6% |
13.2% |
39 of
323 |
| Pain |
Percent of residents who self-report moderate to severe pain (LS) |
9.6% |
14.7% |
93 of
325 |
| For the Quality Indicators below, a higher percentage is better. |
| Functioning |
Walking as well or better than on a previous assessment (LS) |
n/a |
|
n/a of
0 |
| (Date range:
October 1, 2023 to September 30, 2024) |